GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) target price lowered to $133.10, reported today by Goldman Sachs Group Inc.
- Updated: October 6, 2016
Boasting a price of $133.45, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) traded 2.33% higher on the day. With the last close up 50.63% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. GW Pharmaceuticals PLC- ADR has recorded a 50-day moving average of $103.17 and a 200-day moving average of $90.42. 94,791 shares of GWPH traded hands, down from an average volume of 641,034
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) had its target bumped down to $133.10 by Goldman Sachs Group Inc. in an issued report issued 10/07/2016. The dropped target price indicates consistent performance compared to the company's most recent stock price close.
Recent Performance Chart
GW Pharmaceuticals PLC- ADR has with a 52 week low of $35.83 and a 52 week high of $137.88 and has a market cap of $0.
In addition to Goldman Sachs Group Inc. reporting its stock price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $139.75 with 2 brokers rating the stock a strong buy, 5 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. The Company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex R&D segment seeks to maximize the potential of Sativex through the development of indications. The Sativex R&D segment focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Company's cannabinoid technology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.